Talphera, Inc. (TLPH) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Telferra Second Quarter 2026 Financial Results Conference Call. This call is being webcast live via the events page of the Investors Section of Telferra's website at www.telferra.com. You may listen to a replay of this webcast by going to the Investors Section of Telferra's website. I would now like to turn the call over to Raffi Asadorian, Telferra's Chief Financial Officer. Thank you for joining us on the call today. Today we announced our second quarter 2026 financial results and associated business updates in a press release. With me today are Vince Angotti, our Chief Executive Officer, and Dr. Shakil Aslam, Telphera's Chief Medical Officer. Before we begin, I want to remind listeners that during this call, we will likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the operations and future results of telthera. Please refer to our press release in addition to the company's periodic current and annual reports filed with the SEC for a discussion of the risks associated with such forward-looking statements. These documents can also be found on our website within the investors section. I'll now hand the call over to Vince. Thanks, Raffi. Good afternoon, and thank you to everyone joining our call today. We remain on track to complete enrollment in the NEFRO CRRT study later this year. This registrational trial is designed to evaluate whether Nefamistat is a safe and effective anticoagulant for use during continuous renal replacement therapy, or CRRT. The study is being conducted in hospital ICUs with nephrologists leading as principal investigators. With all of our final clinical sites now activated, we have reached 75% enrollment in the nep...